Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Assets (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Non-Current Assets readings, the most recent being $130.8 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 62.51% to $130.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $365.7 million, a 10.12% increase, with the full-year FY2025 number at $76.4 million, down 0.53% from a year prior.
  • Non-Current Assets hit $130.8 million in Q4 2025 for Enanta Pharmaceuticals, up from $76.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $130.8 million in Q4 2025 to a low of $38.2 million in Q4 2023.
  • Median Non-Current Assets over the past 5 years was $74.3 million (2022), compared with a mean of $77.2 million.
  • The widest YoY moves for Non-Current Assets: up 224.03% in 2021, down 64.3% in 2021.
  • Enanta Pharmaceuticals' Non-Current Assets stood at $113.6 million in 2021, then plummeted by 43.83% to $63.8 million in 2022, then crashed by 40.16% to $38.2 million in 2023, then surged by 110.75% to $80.5 million in 2024, then skyrocketed by 62.51% to $130.8 million in 2025.
  • The last three reported values for Non-Current Assets were $130.8 million (Q4 2025), $76.4 million (Q3 2025), and $78.3 million (Q2 2025) per Business Quant data.